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Summary 26
Dermal and systemic infections caused by the Chrysosporium anamorph of Nannizziopsis 27 vriesii (CANV) are highly prevalent in reptiles, resulting in severe disease and high mortality. 28
Due to the high incidence of therapeutic failure, optimizing treatment is required. In this 29 study, at first, the minimal inhibitory concentrations (MIC) of itraconazole, voriconazole, 30 amphotericin B and terbinafine against thirty two CANV isolates were determined. For 31 voriconazole, amphotericin B and terbinafine a monomodal MIC distribution was seen, 32 whereas a bimodal MIC distribution was present for itraconazole, indicating acquired 33 resistance in one isolate. Fourteen naturally infected bearded dragons (Pogona vitticeps), 34 from the same owner, were treated orally either with itraconazole (5 mg/kg q24h) or 35 voriconazole (10 mg/kg q24h). The clinical condition, drug plasma concentrations and the 36 presence of CANV in skin samples were followed up. The animals were treated until 37 complete clearance of the fungus. The plasma concentrations of voriconazole and 38 itraconazole exceeded the minimal inhibitory concentration of the CANV isolate. Elimination 39 of CANV was achieved in 27 and 47 days on average for itraconazole and voriconazole, 40 respectively. Whereas only 2 out of 7 survived after itraconazole treatment, only a single 41 animal died in the voriconazole treated group. In conclusion, based on a limited number of 42 animals, voriconazole applied at a regimen of 10 mg/kg bodyweight (BW) q24h seems to be 43 a safe and effective antimycotic drug to eliminate CANV infections in bearded dragons. 44
Introduction 51
The Chrysosporium anamorph of Nannizziopsis vriesii (CANV) recently emerged as a cause 52 of mycotic dermatitis in different reptile species such as bearded dragons (Pogona 53 vitticeps) [1] Successful treatment of reptiles infected with CANV has been achieved by administering 62 itraconazole in a Parson's chameleon (Chamaeleo parsonii) and in a bearded dragon [1, 2] . 63
Ketoconazole was effective in two green iguanas [3] . However, treatment with antimycotics 64 was often unsuccessful [1, 2] . To optimize the treatment outcome, antifungal drug selection, 65 determination and administration of the optimal dose and frequency of antimycotic drugs are 66 essential. In general, this requires integration of knowledge regarding the drug's 67 pharmacokinetic profile with its antimycotic properties [10] . 68
The use of voriconazole, a novel triazole antifungal agent, has never been described for 69
reptiles. However the in vitro activity of voriconazole against filamentous fungi exceeds that 70 of itraconazole [11] . Azoles inhibit the P450-dependent 14-α-sterol demethylase by which 71 exposed fungi become depleted of ergosterol and accumulate 14-α-methylated sterols. This 72 leads to disruption of membrane function and structure, resulting in fungal growth inhibition 73 [12] . 
Inoculum preparation of the Nannizziopsis vriesii isolates 100
The Nannizziopsis vriesii isolates, grown on Sabouraud dextrose agar for three weeks at 101 30°C, were washed with 5 ml of 1% Tween 20 in sterile phosphate buffered saline (PBS) to 102 harvest conidia. The conidia were adjusted to a concentration of 4x10 6 conidia/ml in PBS by 103 hemocytometer count. These stock conidial suspensions were diluted 1:50 in RPMI 1640 104 medium buffered to pH 7.0 with morpholinepropanesulfonic acid buffer, and dispensed into 105 The MIC endpoint for the azoles and terbinafine was defined as the lowest concentration that 124 produced 80% inhibition compared with the growth in the control well, but for amphotericin 125 B, the endpoint was defined as the lowest concentration with complete inhibition of growth 126 [13] . 127
128

MIC endpoints for Nannizziopsis vriesii isolates 129
The MIC endpoint for the azoles and amphotericin B was defined as the lowest concentration 130 that produced complete inhibition of growth or the first optically clear well, whereas the MIC 131 endpoint for terbinafine was defined as the lowest concentration that produced 80% inhibition 132 compared with the growth in the control well. For all isolates recovered during the antimycotic treatment in the case control study, the MIC 187 of voriconazole was < 0.0313 µg/ml and of itraconazole < 0.0313 µg/ml. 188
The MICs of the quality control strain Candida krusei (ATCC 6258-IHEM 9560) were within 189 the established reference MIC ranges for voriconazole, itraconazole and amphotericin B 190 described by Barry et al., 2000 [13] . No reference range is available for terbinafine. 
